
Arun Sanyal MD
Hepatology & Liver Transplantation
Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine
Join to View Full Profile
1250 E Marshall StRichmond, VA 23298
Phone+1 804-828-6314
Fax+1 804-828-2992
Dr. Sanyal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Virginia Commonwealth University Health SystemFellowship, Gastroenterology, 1987 - 1989
- Texas Tech University (Amarillo)Residency, Internal Medicine, 1984 - 1987
- Maulana Azad Medical CollegeClass of 1981
Certifications & Licensure
- VA State Medical License 1986 - 2026
- NM State Medical License 1986 - 2014
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Clinical Trials
- Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Start of enrollment: 2006 May 01
- Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding Start of enrollment: 2006 Dec 01
- BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis Start of enrollment: 2008 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAcute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone.Kavish R Patidar, Wanzhu Tu, Thomas G Cotter, Douglas A Simonetto, Amon Asgharpour
Hepatology. 2025-04-01 - Discovery of a novel regulator, 3β-sulfate-5-cholestenoic acid, of lipid metabolism and inflammation.Yaping Wang, Arun J Sanyal, Phillip Hylemon, Shunlin Ren
American Journal of Physiology. Endocrinology and Metabolism. 2025-04-01 - 2 citationsacFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.Gong Feng, Ferenc E Mózes, Dong Ji, Sombat Treeprasertsuk, Takeshi Okanoue
Clinical Gastroenterology and Hepatology. 2025-04-01
Journal Articles
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Arun J Sanyal, Gregory Huhn, JAMA
- The Lancet Child & Adolescent HealthArun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
- HSD17B13 Is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non‐Alcoholic Fatty Liver DiseaseElizabeth K Speliotes, Arun J Sanyal, Hepatology
- Join now to see all
Lectures
- Evaluation of Acute Kidney Injury in a Cirrhotic Patient: HRS and BeyondAGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
- Future Therapies for NAFLD/NASHAGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
- Advances in the Management of Cirrhosis and Portal HypertensionAGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
Other
- A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCCArun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-11-20 - A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCCArun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-09-10 - A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCCArun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2013-04-05 - Join now to see all
Authored Content
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Press Mentions
- Phase 3 Trial of Lanifibranor for MASH Completes EnrollmentApril 7th, 2025
- Inventiva Announces Completion of Enrollment in the Phase 3 NATiV3 Clinical Trial of Lanifibranor in Patients with MASH and Advanced FibrosisApril 1st, 2025
- The Link Between Your Heart Health and MASHJanuary 31st, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: